Operational lessons learned in conducting an international study on pharmacovigilance in pregnancy in resource-constrained settings: The WHO Global Vaccine safety Multi-Country collaboration project.
Maternal health
Multi-country Studies
Neonatal health
Pharmacovigilance
Surveillance
Vaccine Safety
Journal
Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
23
09
2021
revised:
03
02
2022
accepted:
04
04
2022
pubmed:
19
4
2022
medline:
19
4
2022
entrez:
18
4
2022
Statut:
ppublish
Résumé
The WHO Global Vaccine Safety Multi-Country Collaboration study on safety in pregnancy aims to estimate the minimum detectable risk for selected perinatal and neonatal outcomes and assess the applicability of standardized case definitions for study outcomes and maternal immunization in low- and middle-income countries (LMICs). This paper documents the operational lessons learned from the study. A prospective observational study was conducted across 21 hospitals in seven countries. All births occurring at sites were screened to identify select perinatal and neonatal outcomes from May 2019 to August 2020. Up to 100 cases per outcome were recruited to assess the applicability of standardized case definitions. A multi-pronged study quality assurance plan was implemented. The impact of the COVID-19 pandemic on site functioning and project implementation was also assessed. Multi-layered ethics and administrative approvals, limited clinical documentation, difficulty in identifying outcomes requiring in-hospital follow-up, and poor quality internet connectivity emerged as important barriers to study implementation. Use of electronic platforms, application of a rigorous quality assurance plan with frequent interaction between the central and site teams helped improve data quality. The COVID-19 pandemic disrupted data collection for up to 6 weeks in some sites. Our study succeeded in establishing an international hospital-based surveillance network for evaluating perinatal and neonatal outcomes using common study protocol and procedures in geographically diverse sites with differing levels of infrastructure, clinical and health-utilization practices. The enhanced surveillance capacity of participating sites shall help support future pharmacovigilance efforts for pregnancy interventions.
Identifiants
pubmed: 35434599
doi: 10.1016/j.jvacx.2022.100160
pii: S2590-1362(22)00020-1
pmc: PMC8993756
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100160Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Vaccine. 2018 Jan 8;36(3):355-362
pubmed: 28780118
J Burn Care Res. 2020 May 2;41(3):681-689
pubmed: 31996926
Vaccine. 2018 Oct 29;36(45):6736-6743
pubmed: 30266486
Vaccine. 2015 Nov 25;33(47):6453-65
pubmed: 26413879
Vaccine. 2014 Dec 12;32(52):7057-64
pubmed: 25285883
BMC Pregnancy Childbirth. 2021 Mar 26;21(Suppl 1):233
pubmed: 33765963
Vaccine. 2019 May 6;37(20):2643-2650
pubmed: 30955981
Bull World Health Organ. 2014 Sep 1;92(9):695-6
pubmed: 25378762
Vaccine. 2016 Dec 1;34(49):5993-5997
pubmed: 27751641
BMC Health Serv Res. 2020 Aug 12;20(1):737
pubmed: 32787852
N Engl J Med. 2017 Mar 30;376(13):1256-1267
pubmed: 28355514
Hum Vaccin Immunother. 2016 Apr 2;12(4):857-65
pubmed: 26552807
BMJ Open. 2021 May 28;11(5):e046827
pubmed: 34049918
Ann Med. 2018 May;50(3):193-208
pubmed: 29308916
BMJ Glob Health. 2018 Oct 15;3(5):e001053
pubmed: 30364289